{'fraction_non_alphanumeric': 0.030666666666666665, 'fraction_numerical': 0.008, 'mean_word_length': 5.310924369747899, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bone loss after cardiac transplantation.

Although clinicians generally consider osteoporosis to be a disease primarily affecting postmenopausal women, other populations are also at high risk. One such group is recipients of organ transplants, who, as their long-term survival improves, have begun to face other medical problems, including osteoporosis. Transplant recipients have generally had long-standing, chronic disease and must receive high doses of antirejection medications designed to suppress their immune system. In this issue of the Journal, Shane et al. (pages 767–776) present data from a randomized trial in which patients who had received a cardiac transplant were given either a bisphosphonate (alendronate) or calcitriol, the . . .